| Document |
Document Title |
|
WO/2017/083681A1 |
The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contracep...
|
|
WO/2017/079907A1 |
Disclosed is a kidney-tonifying medicinal liquor made of the following raw materials: 56-75 g of ginseng, 45-56 g of Achyranthes bidentata, 45-60 g of radix trichosanthis, 16-25 g of angelica, 12-24 g of fructus lycii, 45-60 g of cortex ...
|
|
WO/2017/073764A1 |
The present invention addresses the problem of providing a novel NK3-receptor selective ligand which is expected to have a highly-active/highly-selective and sustained effect in vivo. A compound represented by formula (I) X1-A2-A3-X4-X5-...
|
|
WO/2017/074266A1 |
The invention relates to glyceryl tridecanoate and uses thereof in treating endocrine disorders. More particularly, glyceryl tridecanoate may be used to treat hyper-androgenism, insulin resistance and infertility caused by, for example, ...
|
|
WO/2017/069793A1 |
The presently disclosed subject matter is directed to viscous vaginal pharmaceutical compositions comprising a water soluble gel, methods of making such compositions, and methods of using such compositions to treat vaginal dryness in a s...
|
|
WO/2017/069672A1 |
A pharmaceutical composition for treating infertility in a female subject substantially consists of local anesthetic of amide type such as lidocaine, human albumin, viscosity controlling agent selected from recombinant hyaluronic acid an...
|
|
WO/2017/064815A1 |
An orally disintegrating tablet containing a physiologically active component that exhibits a physiological activity in a trace amount, said orally disintegrating tablet being characterized in that: a) the disintegration time thereof in ...
|
|
WO/2017/064068A1 |
The present invention relates to bicyclic heterocyclic derivatives of Forrmula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by TRPA1...
|
|
WO/2017/064814A1 |
A directly compressed tablet for oral medicines, said tablet comprising (A) fine dienogest particles and (B) at least one kind of excipient particles selected from the group consisting of single D-mannitol particles, single lactose parti...
|
|
WO/2017/061523A1 |
The present invention provides a FOXM1-derived epitope peptide exhibiting cytotoxic T lymphocyte inducibility. The present invention also provides: a polynucleotide encoding said peptide; an antigen-presenting cell presenting said peptid...
|
|
WO/2017/061845A1 |
The invention relates to a pharmaceutical combination comprising a drug for treating sexual disorders, and albumin. The invention also relates to a pharmaceutical formulation for treating sexual disorders, which contains a combination of...
|
|
WO/2017/061522A1 |
The present invention provides an MPHOSPH1-derived epitope peptide exhibiting cytotoxic T lymphocyte inducibility. The present invention also provides: a polynucleotide encoding said peptide; an antigen-presenting cell presenting said pe...
|
|
WO/2017/059726A1 |
Provided in the present invention is a use of a triglyceride compound in the preparation of drugs for treating polycystic ovary syndrome. Also provided in the present invention is a use of a triglyceride compound for preparing a composit...
|
|
WO/2017/055337A1 |
The present invention relates to an aqueous composition comprising apomorphine or a pharmaceutically acceptable salt or solvate thereof, reduced glutathione (GSH) or a pharmaceutically acceptable salt thereof, and ascorbic acid or a phar...
|
|
WO/2017/058175A1 |
The present invention relates to compositions, particularly compositions useful in maintaining and supporting healthy microflora in the female urogenital tract which could lead to inhibition of vaginal infections, as well as methods of t...
|
|
WO/2017/052359A1 |
There is herein disclosed a compound of formula I: or a salt solvate or pharmaceutically acceptable derivative thereof, wherein R1 to R7 is as defined herein for use in the treatment of angenogenis and related conditions.
|
|
WO/2017/049349A1 |
The present invention relates to the treatment or prevention of preeclampsia or symptoms thereof. The use of biomarkers indicative of preeclampsia or a risk of developing preeclampsia is also taught herein.
|
|
WO/2017/050854A1 |
The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concern...
|
|
WO/2017/048801A1 |
It is an object of the present disclosure to provide a formulation for injectable and topical collagenase, which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a fu...
|
|
WO/2017/044003A1 |
The invention relates to the veterinary field. Proposed is a method for temporary blocking sexual function in a male mammal including behavioural phenomena (search for a partner, vocalization, etc.). The method comprises administration o...
|
|
WO/2017/041679A1 |
Provided are a solid dispersion of tadalafil and pharmaceutical excipients, and a preparation method for the solid dispersion. The tadalafil is in an amorphous state. Also provided are a pharmaceutical composition containing the solid di...
|
|
WO/2017/041711A1 |
The invention relates novel pharmaceutical use of kaurane compounds of formula (I) in treating and preventing cardiac hypertrophy and myocardium remodeling. The said compounds also can significantly ameliorate pulmonary hypertension and ...
|
|
WO/2017/040841A1 |
The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, wh...
|
|
WO/2017/034420A1 |
Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, ...
|
|
WO/2017/033170A1 |
The present disclosure relates to a hydrophilic composition, namely a solution comprising at least one phosphodiesterase 5 inhibitor and micronised particles of hyaluronic acid, with mucoadhesion properties and transmucosal transport/car...
|
|
WO/2017/029271A1 |
The present invention relates to lysobactin for use in the treatment of bovine mastitis.
|
|
WO/2017/028025A1 |
Disclosed is a use of a mussel adhesive protein or a preparation thereof for inhibiting a mucosal inflammation. The mucosal inflammation comprises oral mucositis, rhinitis, otitis media, conjunctivitis, pharyngitis, laryngitis, tracheiti...
|
|
WO/2017/031416A1 |
Provided are methods for prophylaxis and/or therapy for a disorder correlated with Brd4 function in brain neurons. The method involves administering to an individual in need thereof a therapeutically effective amount of a Bromodomain and...
|
|
WO/2017/028026A1 |
Disclosed is a use of a mussel adhesive protein or a preparation thereof for mucosal protection, comprising: protecting mucosa from damage caused by ultraviolet, radiation, a high- and low-temperature object, seawater, environmental poll...
|
|
WO/2017/024029A1 |
Technologies are described for formulations and methods to produce a topical formulation. Topical formulations may comprise a β-carboline compound. The β-carboline compound may be in particulate form. The particle size of the particula...
|
|
WO/2017/021435A1 |
The present invention relates to new compounds useful as antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), and in particular to their use as a non-hormonal male contraceptive. The present invention also relates t...
|
|
WO/2017/022095A1 |
[Problem] To promote impregnation in artificial insemination of livestock, provided are an impregnation promoting agent, which is capable of bringing environment for female livestock under artificial insemination closer to natural insemi...
|
|
WO/2017/017511A1 |
A modified release pharmaceutical composition for treating premature ejaculation. The above composition comprises full quantitative timely release (FQTR)of therapeutically effective amounts of active compounds comprising tramadol, rabepr...
|
|
WO/2017/019828A1 |
Disclosed is a compound of Formula (I) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein one R3 is H and the other R3 is an aryl group substituted with zero to 3 R3a; and R1, R2, and R3a a...
|
|
WO/2017/019213A1 |
A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of hot flashes in a female subject, such as experiencing symptoms of perimenopause. The composition includes a phytoestrogen and lycop...
|
|
WO/2017/015334A1 |
Disclosed are methods of diagnosing and treating endometriosis, and in particular, endometriosis-associated infertility.
|
|
WO/2017/014315A1 |
Provided is an EP2 agonist having a high safety. A compound represented by general formula (I) (wherein each symbol is as defined in the description), a salt thereof, an N-oxide derivative thereof, a solvate of the same or a prodrug of t...
|
|
WO/2017/014312A1 |
Provided is an agent for treating/improving female hormone-dependent proliferative diseases containing a low-molecular peptide, especially an erythropoietin mimetic peptide (EMP), in particular EMP9, having an erythropoietin receptor ant...
|
|
WO/2017/014170A1 |
Provided are: a heterocyclic compound which has an HDAC-inhibiting activity and is useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancer, central nervous system diseases including...
|
|
WO2017008737A1 |
Disclosed is a natural medicinal composition for treating involutional melancholia and atypical depressive disorder and use thereof. The formulation of the composition consists in mass percentage of 70%-97.5% sea buckthorn fruit oil and ...
|
|
WO/2017/009472A1 |
The present invention relates to the use of amitriptyline as an inhibitor of connexin hemichannels (HC) in the Central Nervous System (CNS). This HC-blocking agent is advantageously used to treat disorders involving misregulated HC (nota...
|
|
WO2017010515A1 |
[Problem] To provide a therapeutic agent for estrogen-dependent gynecological disorders such as endometriosis, uterine fibroids, and adenomyosis. [Solution] An estrogen receptor α-inhibiting β partial agonist represented by structural ...
|
|
WO/2017/010856A1 |
The invention relates to veterinary medicine and biotechnology, especially with new, natural composition development for the treatment of subclinical mastitis in cows. The aim of invention is to create the effective compositions for the ...
|
|
WO/2017/000082A1 |
Applications of Levonorgestrel in the preparation of products for resisting against ovarian cancer. Applications of Levonorgestrel in the preparation of products for prohibiting proliferation of ovarian cancer cells.
|
|
WO/2017/000270A1 |
The present invention relates to a crystal form A and a crystal form B of sertraline citrate, and preparation methods therefor. The crystal form A and the crystal form B of sertraline citrate have good dissolvability, high dissolution an...
|
|
WO/2017/000080A1 |
Applications of Estrone in the preparation of products for resisting against ovarian cancer and/or breast cancer. Applications of Estrone in the preparation of products for prohibiting proliferations of ovarian cancer cells and breast ca...
|
|
WO/2017/001979A1 |
A composition comprising a dinidolyl methane compound and a cyclooligosaccharide. In addition, a formulation of such a composition as well as to the use of such composition or formulation to treat genital warts and/or neoplastic diseases...
|
|
WO/2017/002865A1 |
Provided is a core-shell structure having high cutaneous permeability. This core-shell structure is provided with a core part containing a hydrophilic drug having a molecular weight of 400 or higher, and a shell part containing a surfact...
|
|
WO/2016/206097A1 |
Disclosed are a compound represented by general formula (I) as a phosphodiesterase type-5 inhibitor or pharmaceutically acceptable salt thereof and use thereof in treating and/or preventing diseases or disease states related to the phosp...
|
|
WO/2016/207298A1 |
Drospirenone as the sole contraceptive ingredient comprised in a daily active dosage unit in an amount of at least 3 mg for use as a contraceptive for a female patient affected with obesity.
|
